SANTA CLARA - HeartBeam, Inc. (NASDAQ:BEAT) is pursuing multiple regulatory paths after receiving a Not Substantially Equivalent (NSE) decision from the Food and Drug Administration (FDA) for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback